Curated News
By: NewsRamp Editorial Staff
March 27, 2026
Sigyn's CardioDialysis Device Aims to Slash Heart Attack and Stroke Rates
TLDR
- Sigyn Therapeutics' CardioDialysis offers a competitive edge by reducing MACE up to 95% using existing dialysis infrastructure for broader patient access.
- CardioDialysis integrates plasma separation and therapeutic adsorption in one device, enabling continuous clearance of inflammatory molecules from the bloodstream on standard dialysis machines.
- This technology could save thousands of lives annually by reducing cardiovascular deaths, making tomorrow better through accessible advanced medical treatment.
- CardioDialysis processes blood more efficiently than complex multi-component systems, addressing a broader range of cardiovascular targets without replacement fluids.
Impact - Why it Matters
Cardiovascular disease is the world's leading cause of death, responsible for millions of fatalities annually, with current treatments often falling short in preventing major adverse events like heart attacks and strokes. This news matters because Sigyn Therapeutics' CardioDialysis technology represents a potential breakthrough that could dramatically improve patient outcomes. By offering a more efficient, accessible, and broad-spectrum alternative to existing therapies, it addresses critical gaps in cardiovascular care. If successfully advanced, this device could reduce healthcare burdens, lower mortality rates, and provide a scalable solution for hospitals and clinics worldwide, ultimately impacting anyone at risk of or affected by heart disease.
Summary
Sigyn Therapeutics, a medical technology company, has unveiled a groundbreaking advancement in cardiovascular treatment through its innovative CardioDialysis device. In a note released by CEO and inventor Jim Joyce, the company highlights how this technology addresses the global crisis of cardiovascular disease, which remains the leading cause of death worldwide. The core message emphasizes that while current treatments like LDL-C reducing statins only reduce major adverse cardiovascular events (MACE) by about 25%, and more effective lipoprotein apheresis devices (such as the FDA-approved Kaneka LIPOSORBER) can achieve reductions of 75-95%, their adoption is limited by complex designs and lack of infrastructure. CardioDialysis overcomes these barriers by integrating plasma separation and therapeutic adsorption into a single, streamlined device deployable on existing dialysis machines in thousands of hospitals and clinics.
Key players include Sigyn Therapeutics (traded as SIGY on OTCQB) and its leadership under Jim Joyce, who authored the note. The technology, CardioDialysis, enables continuous broad-spectrum clearance of inflammatory and pathogenic molecules from the bloodstream, targeting a wider range of cardiovascular disease factors than current apheresis methods. Unlike the multi-component LIPOSORBER system, which requires specialized centers and extensive setup, CardioDialysis is a single-component device that leverages existing dialysis infrastructure, making it more accessible and efficient. This innovation could significantly reduce MACE, including heart attacks and strokes, potentially saving thousands of lives annually by addressing the limitations of single-target drugs and complex apheresis procedures.
The company's broader pipeline includes other therapies like ImmunePrep, ChemoPrep, and ChemoPure, but the focus here is on CardioDialysis's potential to revolutionize cardiovascular care. For more details, readers can visit the company's website at www.SigynTherapeutics.com or view the original release on www.newmediawire.com. This news underscores a pivotal shift in medical technology, offering hope for more effective and widespread treatment options in the fight against cardiovascular disease, which impacts millions globally.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, Sigyn's CardioDialysis Device Aims to Slash Heart Attack and Stroke Rates
